Table 5 Total discounted direct costs, RSV-related hospitalizations, and QALYs of palivizumab vs. placebo in infants with BPD, Colombia, 2022
Outcome | No palivizumab | Palivizumab |
|---|---|---|
Total discounted direct costs | $ 2,970,739 | $ 2,795,546 |
RSV-related hospitalizations | 256 | 157 |
∆ Costs (palivizumab– no palivizumab) | - $ 175,193 | |
∆ QALYs (palivizumab– no palivizumab) | 45 | |